+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Advanced Drug Delivery Systems Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • March 2022
  • Region: Global
  • TechNavio
  • ID: 5561337
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the advanced drug delivery systems market and it is poised to grow by $91.79 bn during 2022-2026 accelerating at a CAGR of 7.41% during the forecast period. The report on advanced drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising chronic diseases and rising investment in research and development of drug delivery.

The advanced drug delivery systems market analysis includes the type segment and geographic landscape.

The advanced drug delivery systems market is segmented as below:


By Type


  • Oral
  • Injection and inhalation
  • Transdermal
  • Carrier-based
  • Others

By Geographical Landscape


  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising healthcare expenditure globally as one of the prime reasons driving the advanced drug delivery systems market growth during the next few years.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The report on advanced drug delivery systems market covers the following areas:
  • Advanced drug delivery systems market sizing
  • Advanced drug delivery systems market forecast
  • Advanced drug delivery systems market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading advanced drug delivery systems market vendors that include 3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. Also, the advanced drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market Characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis: Life Sciences Tools and Services
2.2.1 Research and development
2.2.2 Inputs
2.2.3 Production
2.2.4 Distribution
2.2.5 Marketing and sales
2.2.6 Post-sales and services
2.2.7 Industry innovations
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2026
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ billion)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
The segments covered in this chapter are:
Oral
Injection and inhalation
Transdermal
Carrier-based
Others
Exhibit 22: Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 23: Comparison by Type
5.3 Oral - Market size and forecast 2021-2026
Exhibit 24: Oral - Market size and forecast 2021-2026 ($ billion)
Exhibit 25: Oral - Year-over-year growth 2021-2026 (%)
5.4 Injection and inhalation - Market size and forecast 2021-2026
Exhibit 26: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
Exhibit 27: Injection and inhalation - Year-over-year growth 2021-2026 (%)
5.5 Transdermal - Market size and forecast 2021-2026
Exhibit 28: Transdermal - Market size and forecast 2021-2026 ($ billion)
Exhibit 29: Transdermal - Year-over-year growth 2021-2026 (%)
5.6 Carrier-based - Market size and forecast 2021-2026
Exhibit 30: Carrier-based - Market size and forecast 2021-2026 ($ billion)
Exhibit 31: Carrier-based - Year-over-year growth 2021-2026 (%)
5.7 Others - Market size and forecast 2021-2026
Exhibit 32: Others - Market size and forecast 2021-2026 ($ billion)
Exhibit 33: Others - Year-over-year growth 2021-2026 (%)
5.8 Market opportunity by Type
Exhibit 34: Market opportunity by Type
6. Customer landscape
6.1 Overview
Exhibit 35: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
The regions covered in the report are:
North America
Europe
Asia
ROW
Exhibit 36: Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 37: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 38: North America - Market size and forecast 2021-2026 ($ billion)
Exhibit 39: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 40: Europe - Market size and forecast 2021-2026 ($ billion)
Exhibit 41: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 42: Asia - Market size and forecast 2021-2026 ($ billion)
Exhibit 43: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 44: ROW - Market size and forecast 2021-2026 ($ billion)
Exhibit 45: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 46: Key leading countries
7.9 Market opportunity By Geographical Landscape
Exhibit 47: Market opportunity By Geographical Landscape ($ billion)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Rising chronic diseases
8.1.2 Rising investment in research and development of drug delivery
8.1.3 Rising healthcare expenditure globally
8.2 Market challenges
8.2.1 Presence of stringent regulations
8.2.2 Poor healthcare infrastructure in underdeveloped or developing countries
8.2.3 Biocompatibility and acceptability with human body
Exhibit 48: Impact of drivers and challenges
8.3 Market trends
8.3.1 Covid-19 pandemic to create multiple opportunities in the market
8.3.2 Introduction of targeted drug delivery system
8.3.3 Reduced side effects
9. Vendor Landscape
9.1 Overview
Exhibit 49: Vendor landscape
9.2 Landscape disruption
Exhibit 50: Landscape disruption
Exhibit 51: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 52: Vendors covered
10.2 Market positioning of vendors
Exhibit 53: Market positioning of vendors
10.3 3M Co.
Exhibit 54: 3M Co. - Overview
Exhibit 55: 3M Co. - Business segments
Exhibit 56: 3M Co. - Key offerings
Exhibit 57: 3M Co. - Segment focus
10.4 Alkermes Public Co. Ltd.
Exhibit 58: Alkermes Public Co. Ltd. - Overview
Exhibit 59: Alkermes Public Co. Ltd. - Business segments
Exhibit 60: Alkermes Public Co. Ltd. - Key news
Exhibit 61: Alkermes Public Co. Ltd. - Key offerings
10.5 Antares Pharma Inc.
Exhibit 62: Antares Pharma Inc. - Overview
Exhibit 63: Antares Pharma Inc. - Business segments
Exhibit 64: Antares Pharma Inc. - Key news
Exhibit 65: Antares Pharma Inc. - Key offerings
10.6 Baxter International Inc.
Exhibit 66: Baxter International Inc. - Overview
Exhibit 67: Baxter International Inc. - Business segments
Exhibit 68: Baxter International Inc. - Key offerings
Exhibit 69: Baxter International Inc. - Segment focus
10.7 Becton Dickinson and Co.
Exhibit 70: Becton Dickinson and Co. - Overview
Exhibit 71: Becton Dickinson and Co. - Business segments
Exhibit 72: Becton Dickinson and Co. - Key offerings
Exhibit 73: Becton Dickinson and Co. - Segment focus
10.8 Endo International Plc
Exhibit 74: Endo International Plc - Overview
Exhibit 75: Endo International Plc - Business segments
Exhibit 76: Endo International Plc. - Key news
Exhibit 77: Endo International Plc - Key offerings
Exhibit 78: Endo International Plc - Segment focus
10.9 NanoPass Technologies Ltd.
Exhibit 79: NanoPass Technologies Ltd. - Overview
Exhibit 80: NanoPass Technologies Ltd. - Product and service
Exhibit 81: NanoPass Technologies Ltd. - Key offerings
10.10 Nektar Therapeutics
Exhibit 82: Nektar Therapeutics - Overview
Exhibit 83: Nektar Therapeutics - Product and service
Exhibit 84: Nektar Therapeutics - Key offerings
10.11 Perrigo Co. Plc
Exhibit 85: Perrigo Co. Plc - Overview
Exhibit 86: Perrigo Co. Plc - Business segments
Exhibit 87: Perrigo Co. Plc - Key offerings
Exhibit 88: Perrigo Co. Plc - Segment focus
10.12 Teva Pharmaceutical Industries Ltd.
Exhibit 89: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 90: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 91: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 92: Teva Pharmaceutical Industries Ltd. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objective
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 93: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 94: Research Methodology
Exhibit 95: Validation techniques employed for market sizing
Exhibit 96: Information sources
11.4 List of abbreviations
Exhibit 97: List of abbreviations
List of Exhibits
Exhibit 1: Key Finding 1
Exhibit 2: Key Finding 2
Exhibit 3: Key Finding 3
Exhibit 4: Key Finding 5
Exhibit 5: Key Finding 6
Exhibit 6: Key Finding 7
Exhibit 7: Key Finding 8
Exhibit 8: Parent market
Exhibit 9: Market characteristics
Exhibit 10: Offerings of vendors included in the market definition
Exhibit 11: Market segments
Exhibit 12: Global - Market size and forecast 2021 - 2026 ($ billion)
Exhibit 13: Global market: Year-over-year growth 2021 - 2026 (%)
Exhibit 14: Five forces analysis 2021 & 2026
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition - Five forces 2021
Exhibit 21: Type - Market share 2021-2026 (%)
Exhibit 22: Comparison by Type
Exhibit 23: Oral - Market size and forecast 2021-2026 ($ billion)
Exhibit 24: Oral - Year-over-year growth 2021-2026 (%)
Exhibit 25: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
Exhibit 26: Injection and inhalation - Year-over-year growth 2021-2026 (%)
Exhibit 27: Transdermal - Market size and forecast 2021-2026 ($ billion)
Exhibit 28: Transdermal - Year-over-year growth 2021-2026 (%)
Exhibit 29: Carrier-based - Market size and forecast 2021-2026 ($ billion)
Exhibit 30: Carrier-based - Year-over-year growth 2021-2026 (%)
Exhibit 31: Others - Market size and forecast 2021-2026 ($ billion)
Exhibit 32: Others - Year-over-year growth 2021-2026 (%)
Exhibit 33: Market opportunity by Type
Exhibit 34: Customer landscape
Exhibit 35: Market share By Geographical Landscape 2021-2026 (%)
Exhibit 36: Geographic comparison
Exhibit 37: North America - Market size and forecast 2021-2026 ($ billion)
Exhibit 38: North America - Year-over-year growth 2021-2026 (%)
Exhibit 39: Europe - Market size and forecast 2021-2026 ($ billion)
Exhibit 40: Europe - Year-over-year growth 2021-2026 (%)
Exhibit 41: Asia - Market size and forecast 2021-2026 ($ billion)
Exhibit 42: Asia - Year-over-year growth 2021-2026 (%)
Exhibit 43: ROW - Market size and forecast 2021-2026 ($ billion)
Exhibit 44: ROW - Year-over-year growth 2021-2026 (%)
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity By Geographical Landscape ($ billion)
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Industry risks
Exhibit 51: Vendors covered
Exhibit 52: Market positioning of vendors
Exhibit 53: 3M Co. - Overview
Exhibit 54: 3M Co. - Business segments
Exhibit 55: 3M Co. - Key offerings
Exhibit 56: 3M Co. - Key customers
Exhibit 57: 3M Co. - Segment focus
Exhibit 58: Alkermes Public Co. Ltd. - Overview
Exhibit 59: Alkermes Public Co. Ltd. - Business segments
Exhibit 60: Alkermes Public Co. Ltd. - Key offerings
Exhibit 61: Alkermes Public Co. Ltd. - Key customers
Exhibit 62: Alkermes Public Co. Ltd. - Segment focus
Exhibit 63: Antares Pharma Inc. - Overview
Exhibit 64: Antares Pharma Inc. - Business segments
Exhibit 65: Antares Pharma Inc. - Key offerings
Exhibit 66: Antares Pharma Inc. - Key customers
Exhibit 67: Antares Pharma Inc. - Segment focus
Exhibit 68: Baxter International Inc. - Overview
Exhibit 69: Baxter International Inc. - Business segments
Exhibit 70: Baxter International Inc. - Key offerings
Exhibit 71: Baxter International Inc. - Key customers
Exhibit 72: Baxter International Inc. - Segment focus
Exhibit 73: Becton Dickinson and Co. - Overview
Exhibit 74: Becton Dickinson and Co. - Business segments
Exhibit 75: Becton Dickinson and Co. - Key offerings
Exhibit 76: Becton Dickinson and Co. - Key customers
Exhibit 77: Becton Dickinson and Co. - Segment focus
Exhibit 78: Endo International Plc - Overview
Exhibit 79: Endo International Plc - Business segments
Exhibit 80: Endo International Plc - Key offerings
Exhibit 81: Endo International Plc - Key customers
Exhibit 82: Endo International Plc - Segment focus
Exhibit 83: NanoPass Technologies Ltd. - Overview
Exhibit 84: NanoPass Technologies Ltd. - Product and service
Exhibit 85: NanoPass Technologies Ltd. - Key offerings
Exhibit 86: NanoPass Technologies Ltd. - Key customers
Exhibit 87: NanoPass Technologies Ltd. - Segment focus
Exhibit 88: Nektar Therapeutics - Overview
Exhibit 89: Nektar Therapeutics - Product and service
Exhibit 90: Nektar Therapeutics - Key offerings
Exhibit 91: Nektar Therapeutics - Key customers
Exhibit 92: Nektar Therapeutics - Segment focus
Exhibit 93: Perrigo Co. Plc - Overview
Exhibit 94: Perrigo Co. Plc - Business segments
Exhibit 95: Perrigo Co. Plc - Key offerings
Exhibit 96: Perrigo Co. Plc - Key customers
Exhibit 97: Perrigo Co. Plc - Segment focus
Exhibit 98: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 99: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 100: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 101: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 102: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 103: Currency conversion rates for US$
Exhibit 104: Research Methodology
Exhibit 105: Validation techniques employed for market sizing
Exhibit 106: Information sources
Exhibit 107: List of abbreviations

Executive Summary

The publisher announces the Publication of its Research Report - Global Advanced Drug Delivery Systems Market 2022-2026

The publisher recognizes the following companies as the key players in the global advanced drug delivery systems market: 3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is rising healthcare expenditure globally.'

According to the report, one of the major drivers for this market is the rising chronic diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3M Co.
  • Alkermes Public Co. Ltd.
  • Antares Pharma Inc.
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Endo International Plc
  • NanoPass Technologies Ltd.
  • Nektar Therapeutics
  • Perrigo Co. Plc
  • Teva Pharmaceutical Industries Ltd.